Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All iSpecimen Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, iSpecimen Inc. reported a net loss of $5.85 million on revenue of $551,983, a significant decrease from $1.88 million in revenue for the same period in 2025. The company strengthened its balance sheet through PIPE financings totaling $7.5 million and executed a 1-for-40 reverse stock split in April 2026.
iSpecimen Inc. entered into a securities purchase agreement with accredited investors for a private placement of 500 shares of Series D Convertible Preferred Stock at $800 per share. The offering generated gross proceeds of $400,000, which the company intends to use for working capital and general corporate purposes. E.F. Hutton & Co. served as the exclusive placement agent for the transaction.
iSpecimen Signs $4.5M M&A Deal with Foldlab AI Ltd.
iSpecimen Inc. completed the acquisition of AI software assets from Foldlab AI Ltd. for an aggregate purchase price of $4.5 million, consisting of $750,000 in cash, $1.25 million in milestone payments, and $2.5 million in common stock. The acquired assets include a Disease-Associated Protein Discovery AI Agent and a Disease Trend Prediction and Monitoring AI Model, marking the company's entry into AI-powered drug discovery.
iSpecimen Inc. stockholders approved an amendment to the company's Certificate of Incorporation to effect a reverse stock split. The approved ratio range is between 1-for-10 and 1-for-100, with the final ratio to be determined by the Board of Directors.